Arcoscreen

Executive Summary

Arcoscreen is a Swiss biotechnology company founded in 2020 and headquartered in Geneva. The company has developed Arcoflow, a proprietary platform that enables the screening of G protein-coupled receptor (GPCR) drugs directly in primary patient cells. By allowing pharmaceutical companies to evaluate drug candidates in a more physiologically relevant context, Arcoscreen aims to accelerate the transition from preclinical research to clinical trials, addressing a critical bottleneck in GPCR drug development. The platform's ability to work with patient-derived cells could improve the predictive accuracy of early-stage drug screening, potentially reducing late-stage failures and development costs. As a private, early-stage company, Arcoscreen has not disclosed its funding history or valuation. Its success hinges on securing partnerships with pharmaceutical firms and demonstrating the platform's utility in real-world drug discovery programs. The company operates in the competitive diagnostics and infectious disease space, but its focus on GPCRs—a highly druggable target class—positions it well for collaboration. While specific near-term milestones are not public, Arcoscreen's innovative approach and strong scientific foundation suggest potential for growth. Conviction is moderate given the lack of disclosed traction, but the technology addresses a genuine need in drug discovery.

Upcoming Catalysts (preview)

• Q3 2026First pharmaceutical partnership agreement45% success
• Q4 2026Publication of proof-of-concept data in a peer-reviewed journal60% success
• H1 2027Series A funding round announcement50% success